News & Updates | The Sage Group

Sage Group News

The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist

In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to...

AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease

Birmingham, Alabama, and London, England, 1 September 2022 – AeroNeph Therapeutics (“AeroNeph”; www.aeroneph.com), a pioneer in discovery...

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

See full Press Release by clicking the link below!

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges,...

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®. Xeglyze is a patent protected, single...

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Our new client DisperSol Technologies, Inc. (https://www.dispersoltech.com/) is a private, Austin, Texas-based drug development company...

Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem

Glycostem Therapeutics B.V. (“Glycostem” or the “Company”). Glycostem is a cell therapy company focused on developing stem cell-derived...